Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $183M |
| Revenue Growth (YOY): 47.69% |
| Profit (% of Rev): 98.43% |
| Income (% of Rev): 25.86% |
| Income Growth (YOY): 50.47% |
| Operating Income: $47M |
| Operating Cash Flow: $74M |
| Operating Cash Flow Growth (YoY): 39.54% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $784M |
| Total Liabilities: $145M |
| Cash & Equivalent: $137M |
| Total Debt: $7M |
| Debt/Equity: 0.01 |
| Quick Ratio: 3.64 |
| Current Ratio: 3.70 |
| Price/Book: 7.49 |
| Price/Earnings: 25.33 |
| EBITDA: $47M |
| EPS: 0.45 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.